ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of ...

Kymera Therapeutics Inc (KYMR) showcases robust financial health and strategic pipeline advancements amid competitive ...

This study was limited by its observational design, the exclusion of children with severe CMPA or significant comorbidities, and a lack of data on gut microbiota and Th1/Th2 cytokines. Randomized ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

Improper self-antigen recognition by DCs and T-cell initiates, through release of specific cytokines (as described above), destructive Th1 or Th2 responses. RA, for example, is characterized by an ...

Considering that IL-21 primarily participates in regulating the fate of Tfh and Th17/Treg cells, but not as a definitive cytokine for Th1/Th2 lineage differentiation, this section does not further ...